# Thyroid Eye Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/thyroid-eye-disease

> 2 upcoming FDA catalysts in thyroid Eye Disease: AMG-732 (AMGN) on Jan to Apr 2028 (topline data readout); AMG-732 (AMGN) on January 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 1, 2025 | [Lumvoa™ (veligrotug) primary completion](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547)) |
| 2H 2025 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT | thyroid eye disease | scheduled | "Additionally, top-line results for batoclimab from potentially registrational Phase 3 trials in thyroid eye disease are expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/a2025q1ex991.htm)) |
| November 2, 2025 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05517421 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517421)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307613 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307613)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307626 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307626)) |
| December 23, 2025 | [TEPEZZA® (teprotumumab) primary completion](https://sec-api.dev/pdufa/teprotumumab) | AMGN | Thyroid Eye Disease | completed | "NCT06248619 (A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06248619)) |
| February 3, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05524571 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05524571)) |
| February 12, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625411 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625411)) |
| March 4, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625398 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625398)) |
| April 2, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | withdrawn | "NCT05517447 (Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517447)) |
| May 28, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT07155668 (A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155668)) |
| June 26, 2026 | [Lumvoa™ (veligrotug) FDA approval](https://sec-api.dev/pdufa/veligrotug) | VRDN | thyroid eye disease | completed, approved | "On June 26, 2026, Viridian Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease ("TED") regardless of activity or duration." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm)) |
| August 13, 2026 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | Thyroid Eye Disease | completed | "NCT06384547 (A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-01 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06384547?tab=results)) |
| Jan to Apr 2028 | [AMG-732 topline data readout](https://sec-api.dev/pdufa/amg-732) | AMGN | Thyroid Eye Disease | scheduled | "NCT07438405 (An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-29 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438405)) |
| January 2028 | [AMG-732 primary completion](https://sec-api.dev/pdufa/amg-732) | AMGN | Thyroid Eye Disease | scheduled | "NCT07438405 (An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-29 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438405)) |

## Drugs

- [Lumvoa™ (veligrotug)](https://sec-api.dev/pdufa/veligrotug) (VRDN)
- [Batoclimab](https://sec-api.dev/pdufa/batoclimab) (IMVT)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [TEPEZZA® (teprotumumab)](https://sec-api.dev/pdufa/teprotumumab) (AMGN)
- [VRDN-003](https://sec-api.dev/pdufa/vrdn-003) (VRDN)
- [AMG-732](https://sec-api.dev/pdufa/amg-732) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/thyroid-eye-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Thyroid Eye Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/thyroid-eye-disease

```bibtex
@misc{secapidev_indications_thyroid_eye_disease_20261116,
  title        = {Thyroid Eye Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/thyroid-eye-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_thyroid_eye_disease_20261116","title":"Thyroid Eye Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/thyroid-eye-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
